Seres Therapeutics, Inc. (MCRB)
MCRB Stock Price Chart
Explore Seres Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze MCRB price movements and trends.
MCRB Company Profile
Discover essential business fundamentals and corporate details for Seres Therapeutics, Inc. (MCRB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jun 2015
Employees
103.00
CEO
Richard N. Kender
Description
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
MCRB Financial Timeline
Browse a chronological timeline of Seres Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$2.19, while revenue estimate is $179.00k.
Earnings released on 5 May 2026
EPS came in at -$2.08 falling short of the estimated -$1.88 by -10.64%, while revenue for the quarter reached $358.00k , meeting expectations.
Earnings released on 12 Mar 2026
EPS came in at -$1.89 surpassing the estimated -$2.39 by +20.92%, while revenue for the quarter reached $438.00k , missing expectations by -91.74%.
Earnings released on 5 Nov 2025
EPS came in at $0.94 surpassing the estimated $0.05 by +1.78k%, while revenue for the quarter reached $351.00k , missing expectations by -95.52%.
Earnings released on 6 Aug 2025
EPS came in at -$2.27 surpassing the estimated -$2.72 by +16.54%.
Earnings released on 7 May 2025
EPS came in at -$2.24 falling short of the estimated -$0.67 by -234.33%.
Stock split effective on 22 Apr 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Mar 2025
EPS came in at -$0.32 falling short of the estimated -$0.17 by -88.24%.
Earnings released on 13 Nov 2024
EPS came in at -$6.60 falling short of the estimated -$5.00 by -32.00%.
Earnings released on 13 Aug 2024
EPS came in at -$4.40 surpassing the estimated -$5.60 by +21.43%.
Earnings released on 8 May 2024
EPS came in at -$5.40 surpassing the estimated -$7.20 by +25.00%.
Earnings released on 5 Mar 2024
EPS came in at -$6.40 surpassing the estimated -$8.00 by +20.00%, while revenue for the quarter reached $64.00k , missing expectations by -81.71%.
Earnings released on 2 Nov 2023
EPS came in at -$7.40 surpassing the estimated -$9.40 by +21.28%, while revenue for the quarter reached $310.00k , missing expectations by -11.43%.
Earnings released on 8 Aug 2023
EPS came in at $7.20 falling short of the estimated $11.00 by -34.55%, while revenue for the quarter reached $126.47m , beating expectations by +0.61%.
Earnings released on 9 May 2023
EPS came in at -$11.40 matching the estimated -$11.40, while revenue for the quarter reached -$522.00k , missing expectations by -137.83%.
Earnings released on 7 Mar 2023
EPS came in at -$10.80 falling short of the estimated -$8.20 by -31.71%, while revenue for the quarter reached $975.00k , missing expectations by -83.75%.
Earnings released on 2 Nov 2022
EPS came in at -$9.80 falling short of the estimated -$9.00 by -8.89%, while revenue for the quarter reached $3.44m , missing expectations by -50.83%.
Earnings released on 3 Aug 2022
EPS came in at -$14.00 falling short of the estimated -$11.60 by -20.69%, while revenue for the quarter reached $1.22m , missing expectations by -73.23%.
Earnings released on 4 May 2022
EPS came in at -$12.20 falling short of the estimated -$11.20 by -8.93%, while revenue for the quarter reached $1.49m , missing expectations by -82.41%.
Earnings released on 1 Mar 2022
EPS came in at -$11.00 falling short of the estimated -$9.00 by -22.22%, while revenue for the quarter reached $7.22m , missing expectations by -41.07%.
Earnings released on 10 Nov 2021
EPS came in at $14.40 surpassing the estimated -$9.40 by +253.19%, while revenue for the quarter reached $126.73m , missing expectations by -68.54%.
Earnings released on 3 Aug 2021
EPS came in at -$10.60 falling short of the estimated -$8.20 by -29.27%, while revenue for the quarter reached $5.26m , missing expectations by -2.36%.
MCRB Stock Performance
Access detailed MCRB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
